AB0553 BASELINE DISEASE ACTIVITY AS A PREDICTOR FOR ACHIEVING cDAPSA TREATMENT TARGETS WITH APREMILAST IN DMARD-NAIVE PATIENTS WITH MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS

Background: In PALACE 4, DMARD-naive patients (pts) with moderately active (ModDA) psoriatic arthritis (PsA) at baseline (BL) were more likely to achieve Clinical Disease Activity Index for PsA (cDAPSA) treatment targets (cDAPSA remission [REM] or low disease activity [LDA]) Week 52 continued apremilast 30 mg BID (APR) than pts high (HDA) BL. Pts who achieved cDAPSA also had no mild articular and extra-articular by 52. Whether specific manifestations other impact the achievement of in this population is unknown. Objectives: To assess predictive value BL clinical status on achieving 4 ModDA HDA exhibited skin involvement, enthesitis, and/or dactylitis Methods: This post hoc analysis included APR-treated available data any BL, including skin-involved body surface area (BSA) ≥3%, Maastricht Ankylosing Spondylitis Entheses Score (MASES) >0, count >0. divided into subgroups based number manifestations: ≥1, only 1, 2, all 3. The proportions shifted across (>13 ≤27) (>27) categories REM (≤4) LDA (>4 ≤13) calculated (data as observed). Results: 176 receiving APR, 165 involvement ≥1 manifestation addition peripheral (ie, skin/enthesitis/dactylitis) a mean age 48.8 years, duration 3.6 Psoriasis Area Severity (PASI) score 6.6, MASES 3.8, 3.5 (Table 1). Within subgroup, 32.7% 1 these non-arthritic manifestations, 50.9% 16.4% manifestation, greater proportion REM/LDA those (66.7% vs 32.2%; risk difference: 0.34) (Figure Similarly, rates target observed (72.2% 39.1%; 0.33), 2 (57.1% 28.6%; 0.29), 3 (75.0% 33.3%; 0.42) Conclusion: exhibiting various skin/enthesitis/dactylitis), APR HDA. observation was consistent whether multiple manifestations. These findings are probability demonstrated overall (61.7% 28.2% HDA). Table 1. Demographics Characteristics With Manifestations (Skin Involvement, Enthesitis, Dactylitis) Treated (N = 165) Age*, years (12.5) Women, n (%) 87 (52.7) BMI*, kg/m 29.9 (6.5) Duration PsA*, (5.0) psoriasis*, 15.5 (13.3) (0-154)* 39.4 (19.7) Swollen joint (0-66)* 10.3 (7.7) Tender (0-68)* 18.5 (12.9) Pt’s Assessment Pain (VAS 0-100 mm)* 52.8 (21.5) Global 53.8 (20.1) Physician’s 52.2 (17.6) PASI (0-72)* ,† 6.6 (5.1) (0-13)* ,‡ 3.8 (3.0) Dactylitis (0-20)* ,§ (3.3) Corticosteroid use, 13 (7.9) NSAID 126 (76.4) *Mean (SD). † BSA ≥3% ‡ enthesitis § Acknowledgements: study funded Celgene. Additional analyses Amgen Inc. Writing support provided Kristin Carlin, RPh, MBA, Peloton Advantage, LLC, an OPEN Health company. Figure Disclosure Interests: Philip J Mease Speakers bureau: AbbVie, Inc., Eli Lilly, Janssen, Novartis, Pfizer, UCB, Consultant of: Boehringer Ingelheim, BMS, Celgene, Galapagos, GSK, Sun, Grant/research from: Arthur Kavanaugh AstraZeneca, Centocor-Janssen, Roche, Alexis Ogdie Corrona, Gilead, Novartis Alvin F. Wells Alexion, Horizon, Martin Bergman Shareholder Johnson & Johnson, Sanofi, Genentech, Merck, Dafna D Gladman Amgen, Celgene Corporation, Frank Behrens Biotest, Chugai, Genzyme, Yuri Klyachkin Employee Sven Richter Lichen Teng Josef S. Smolen Astro, Celtrion, Glaxo, ILTOO, Medimmune, MSD, Samsung, Roche.